<HashMap><database>ecrin-mdr-crc</database><scores/><additional><omics_type>Clinical</omics_type><study_start_year>2001</study_start_year><condition>Colorectal Cancer</condition><condition>Colorectal Neoplasms</condition><disease>Colorectal Cancer</disease><disease>Colorectal Neoplasms</disease><study_type>Interventional</study_type><full_dataset_link>https://newmdr.ecrin.org/Study/2008391</full_dataset_link><location>United States</location><study_start_month>10</study_start_month><keyword>Irinotecan</keyword><keyword>Capecitabine</keyword><repository>ECRIN MDR</repository><study_status>Completed</study_status></additional><is_claimable>false</is_claimable><name>A Study of Xeloda (Capecitabine) in Patients With Advanced and/or Metastatic Colorectal Cancer</name><description>This study will assess the efficacy and safety of intermittent oral Xeloda administration in combination with irinotecan as a first-line treatment in patients with advanced and/or metastatic colorectal cancer. The anticipated time on study treatment is 3-12 months and the target sample size is &lt;100 individuals.</description><dates><creation>2001-10-15</creation></dates><accession>2008391</accession><cross_references><ClinicalTrials___gov>NCT00048139</ClinicalTrials___gov></cross_references></HashMap>